Sarepta Therapeutics
Sarepta Therapeutics is an American biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company is primarily known for its work in Duchenne muscular dystrophy (DMD) treatments.
History[edit | edit source]
Founded in 1980 as AntiVirals Inc., the company initially focused on developing treatments for infectious diseases. In 2003, it was renamed AVI BioPharma and shifted its focus to RNA-based therapeutics. In 2012, the company adopted its current name, Sarepta Therapeutics, and began to concentrate on rare genetic disorders, particularly DMD.
Research and Development[edit | edit source]
Sarepta Therapeutics' research and development efforts are primarily focused on genetic diseases, with a significant emphasis on DMD. The company's lead product, Eteplirsen (brand name Exondys 51), received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2016. This marked the first FDA-approved treatment specifically for DMD.
The company is also developing other RNA-targeted and gene therapy candidates for the treatment of DMD and other rare genetic diseases. These include Golodirsen (Vyondys 53) and Casimersen (Amondys 45), both of which have received FDA approval.
Financials[edit | edit source]
As a biopharmaceutical company, Sarepta Therapeutics' revenue primarily comes from the sales of its approved drugs. The company also receives funding from various research grants and collaborations with other pharmaceutical and biotechnology companies.
Criticism and Controversy[edit | edit source]
Sarepta Therapeutics has faced criticism and controversy, particularly regarding the accelerated approval of Eteplirsen by the FDA. Critics argue that the approval was based on insufficient evidence of the drug's effectiveness.
See Also[edit | edit source]
References[edit | edit source]
Transform your life with W8MD's budget GLP1 injections from $125 and up biweekly
W8MD offers a medical weight loss program NYC and a clinic to lose weight in Philadelphia. Our W8MD's physician supervised medical weight loss centers in NYC provides expert medical guidance, and offers telemedicine options for convenience.
Why choose W8MD?
- Comprehensive care with FDA-approved weight loss medications including:
- loss injections in NYC both generic and brand names:
- weight loss medications including Phentermine, Qsymia, Contrave, Diethylpropion etc.
- Accept most insurances for visits or discounted self pay cost.
- Generic weight loss injections starting from just $125.00 for the starting dose
- In person weight loss NYC and telemedicine medical weight loss options in New York city available
Book Your Appointment
Start your NYC weight loss journey today at our NYC medical weight loss, and Philadelphia and visit Philadelphia medical weight loss Call (718)946-5500 for NY and 215 676 2334 for PA
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's NYC physician weight loss.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available. Call 718 946 5500.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD